MSMaciej Sroczyński

Maciej Sroczyński

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maciej Sroczyński has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Thrombosis of a femoropopliteal vein graft as a complication of COVID-19 vaccination, with subsequent recanalization of the graft following gene therapy

    by Paweł Lubieniecki, Maciej Antkiewicz, Katarzyna Frączkowska-Sioma, Wojciech Sekula, Mateusz Szmit, Maciej Sroczyński, Gabriela Augustynowicz, Maria Lasocka, Jan Barć, Bartosz Adamiec, et al.

  • Open Access

    Gallstones, obesity, insulin resistance, and obstructive sleep apnea – current knowledge on the topic: A literature review

    by Weronika Frosztęga, Maciej Sroczyński, Monika Michałek, Mieszko Więckiewicz, Katarzyna Madziarska, Helena Martynowicz

    Cholelithiasis is one of the most common gastrointestinal diseases, which often manifests asymptomatically. Statistically, up to 20% of the global population is affected by gallbladder diseases. The prevalence of these conditions rapidly increases with the patient's age. Obstructive sleep apnea (OSA) is a sleeprelated breathing disorder that causes pharyngeal airway collapse, hypopnea and snoring. It is estimated that nearly half of the global population suffer from OSA. Cholelithiasis and OSA are separate medical conditions. However, they both affect a significant part of the general population, have tremendous impact on patients' overall health, and share common risk factors, pathophysiology and disease development.Thus, the aim of this brief narrative review is to summarize and update the current knowledge on the link between gallstone disease and OSA regarding the prevalence of obesity and insulin resistance in patients with both OSA and cholelithiasis.


  • Open Access

    Sex Differences in Patients with MASLD and Their Association with Cardiometabolic Risk Factors: Insights from the Polish Gallstone Surgery Registry

    by Iwona Gorczyca-Głowacka, Magdalena Kołomańska, Robert Mazurkiewicz, Marcin Niżnik, Krzysztof Ratnicki, Małgorzata Czerniak, Piotr Myrcha, Sebastian Lenarcik, Kryspin Mitura, Laura Kacprzak, et al.

    Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by the presence of hepatic steatosis and at least one cardiometabolic risk factor. Differences in the incidence of MASLD between men and women are primarily due to distinct metabolic and cardiovascular profiles. The aim of this observational study was to investigate the prevalence and characteristics of MASLD in men and women. Methods: The study included patients from the Polish Gallstone Surgery Registry diagnosed with MASLD according to current criteria. Results: Among 3419 patients, MASLD was diagnosed in 24.2%. Its prevalence was significantly higher in men (29.8%) than in women (21.9%) (p < 0.0001), with the highest incidence observed in men aged 70–79 (32.1%) and women aged 70–79 (33.3%). MASLD was associated with overweight in individuals aged < 50 years (OR 1.87; 95% CI: 1.11–3.14; p < 0.0186) and in those aged ≥ 50 years (OR 1.99; 95% CI: 1.48–2.68; p < 0.001), as well as with obesity in patients aged < 50 years (OR 6.53; 95% CI: 4.08–10.47; p < 0.001) and in those aged ≥ 50 years (OR 3.9; 95% CI: 2.92–5.22; p < 0.0001). Conclusions: In this study, MASLD was diagnosed more frequently in men than in women, and its incidence showed a positive association with increasing BMI. These findings indicate that excess body weight and sex are key predictors of MASLD, highlighting the need for individualized treatment strategies.


  • Open Access

    Sex Differences in Patients with MASLD and Their Association with Cardiometabolic Risk Factors: Insights from the Polish Gallstone Surgery Registry

    by Iwona Gorczyca-Głowacka, Magdalena Kołomańska, Robert Mazurkiewicz, Marcin Niżnik, Krzysztof Ratnicki, Małgorzata Czerniak, Piotr Myrcha, Sebastian Lenarcik, Kryspin Mitura, Laura Kacprzak, et al.

    Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined by the presence of hepatic steatosis and at least one the cardiometabolic risk factors. Differences in the incidence of MASLD between men and women are primarily due to distinct metabolic and cardiovascular profiles. The aim of this observational study was to investigate the prevalence and characteristics of MASLD in men and women. Methods: The study included patients from The Polish Gallstone Surgery Registry diagnosed with MASLD according to current criteria. Results: Among 3419 patients, MASLD was diagnosed in 24.2%. Its prevalence was significantly higher in man (29.8%) than in women (21.9%) (p< 0.0001), with the highest incidence observed in men aged 70-79 (32.1%) and women aged 70-79 (33.3%). MASLD was associated with overweight in both men (OR 1.60; 95% CI: 1.03–2.48) and women (OR 2.45; 95% CI: 1.80–3.35), as well as with obesity in men (OR 3.44; 95% CI: 2.21–5.34) and women (OR 5.51; 95% CI: 4.10–7.40). Conclusions: In this study, MASLD was diagnosed more frequently in men than in women. The incidence of MASLD increased with age and BMI, with this relationship being more pronounced in women. Therefore, age and excess body weight are key predictors of MASLD, highlighting the need for individualized treatment strategies, regardless of gender.


  • Open Access

    Liver Function Tests in COVID-19: Assessment of the Actual Prognostic Value

    by Urszula Tokarczyk, Krzysztof Kaliszewski, Anna Kopszak, Łukasz Nowak, Karolina Sutkowska-Stępień, Maciej Sroczyński, Monika Sępek, Agata Dudek, Dorota Diakowska, Małgorzata Trocha, et al.

    Deviations in laboratory tests assessing liver function in patients with COVID-19 are frequently observed. Their importance and pathogenesis are still debated. In our retrospective study, we analyzed liver-related parameters: aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), total bilirubin (TBIL), albumin, comorbidities and other selected potential risk factors in patients admitted with SARS-CoV-2 infection to assess their prognostic value for intensive care unit admission, mechanical ventilation necessity and mortality. We compared the prognostic effectiveness of these parameters separately and in pairs to the neutrophil-to-lymphocyte ratio (NLR) as an independent risk factor of in-hospital mortality, using the Akaike Information Criterion (AIC). Data were collected from 2109 included patients. We created models using a sample with complete laboratory tests n = 401 and then applied them to the whole studied group excluding patients with missing singular variables. We estimated that albumin may be a better predictor of the COVID-19-severity course compared to NLR, irrespective of comorbidities (p < 0.001). Additionally, we determined that hypoalbuminemia in combination with AST (OR 1.003, p = 0.008) or TBIL (OR 1.657, p = 0.001) creates excellent prediction models for in-hospital mortality. In conclusion, the early evaluation of albumin levels and liver-related parameters may be indispensable tools for the early assessment of the clinical course of patients with COVID-19.


  • Open Access

    Assessment of Gastrointestinal Symptoms and Dyspnea in Patients Hospitalized due to COVID-19: Contribution to Clinical Course and Mortality

    by Krzysztof Kaliszewski, Dorota Diakowska, Łukasz Nowak, Urszula Tokarczyk, Maciej Sroczyński, Monika Sępek, Agata Dudek, Karolina Sutkowska-Stępień, Katarzyna Kiliś-Pstrusińska, Agnieszka Matera-Witkiewicz, et al.

    Gastrointestinal manifestations may accompany the respiratory symptoms of COVID-19. Abdominal pain (AP) without nausea and vomiting is one of the most common. To date, its role and prognostic value in patients with COVID-19 is still debated. Therefore, we performed a retrospective analysis of 2184 individuals admitted to hospital due to COVID-19. We divided the patients into four groups according to presented symptoms: dyspnea, n = 871 (39.9%); AP, n = 97 (4.4%); AP with dyspnea together, n = 50 (2.3%); and patients without dyspnea and AP, n = 1166 (53.4%). The patients with AP showed tendency to be younger than these with dyspnea, but without AP (63.0 [38.0–70.0] vs. 65.0 [52.0–74.0] years, p = 0.061), and they were more often females as compared to patients with dyspnea (57.7% vs. 44.6%, p = 0.013, for females). Patients with AP as a separate sign of COVID-19 significantly less often developed pneumonia as compared to individuals with dyspnea or with dyspnea and AP together (p < 0.0001). Patients with AP or AP with dyspnea were significantly less frequently intubated or transferred to the intensive care unit (p = 0.003 and p = 0.031, respectively). Individuals with AP alone or with dyspnea had significantly lower rate of mortality as compared to patients with dyspnea (p = 0.003). AP as a separate symptom and also as a coexisting sign with dyspnea does not predispose the patients with COVID-19 to the worse clinical course and higher mortality.